The K101P and K103R/V179D mutations in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nonnucleoside reverse transcriptase inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 1, 2006, Pages 351-354

  Parkin, Neil T ^a   Gupta, Soumi ^a   Chappey, Colombe ^a   Petropoulos, Christos J ^a  

^a MONOGRAM BIOSCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DELAVIRDINE; EFAVIRENZ; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; NONHUMAN; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; VIRUS GENE;

AMINO ACID SUBSTITUTION; CODON; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 29944445797     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.1.351-354.2006     Document Type: Article

References (15)

1. Benjamini, Y., and Y. Hochberg. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B 57:289-300.
2. Boyer, P. L., H.-Q. Gao, and S. H. Hughes. 1998. A mutation at position 190 of human immunodeficiency virus type I reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer. Antimicrob. Agents Chemother. 42:447-452.
3. Harrigan, P. R., T. Mo, B. Wynhoven, J. Hirsch, Z. Brumme, P. McKenna, T. Pattery, J. Vingerhoets, and L. T. Bacheler. 2005. Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to nonnucleoside reverse transcriptase inhibitors. AIDS 19:549-554.
4. Huang, W., A. Gamarnik, K. Limoli, C. J. Petropoulos, and J. M. Whitcomb. 2003. Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication. J. Virol. 77:1512-1523.
5. Kleim, J. P., R. Bender, R. Kirsch, C. Meichsner, A. Paessens, and G. Riess. 1994. Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase. Virology 200:696-701.
6. Munoz, M., R. Carmona, L. Perez-Alvarez, G. Cilla, M. D. Suarez, E. Delgado, G. Contreras, J. Corral, M. J. de Goicoetxea, L. Medrano, M. J. Lezaun, and R. Najera. 2005. Analysis of discrepancies in the interpretation of antiretroviral drug resistance results in HIV-1 infected patients of Basque Country. Spain. J. Clin. Virol. 33:224-229.
7. Nunberg, J. H., W. A. Schleif, E. J. Boots, J. A. O'Brien, J. C. Quintero, J. M. Hoffman, E. A. Emini, and M. E. Goldman. 1991. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J. Virol. 65:4887-4892.
8. Parkin, N., C. Chappey, L. Maroldo, M. Bates, N. S. Hellmann, and C. J. Petropoulos. 2002. Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information. J. Acquir. Immune Defic. Syndr. 31:128-136.
9. Parkin, N. T., N. S. Hellmann, J. M. Whitcomb, L. Kiss, C. Chappey, and C. J. Petropoulos. 2004. Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 48:437-443.
10. Richman, D. D., D. Havlir, J. Corbeil, D. Looney, C. Ignacio, S. A. Spector, J. Sullivan, S. Cheeseman, K. Barringer, D. Pauletti, et al. 1994. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68:1660-1666.
11. Sarkar, G., and S. S. Sommer. 1990. The "megaprimer" method of site-directed mutagenesis. BioTechniques 8:404-407.
12. Sarmati, L., E. Nicastri, S. G. Parisi, G. d'Ettorre, G. Mancino, P. Narciso, V. Vullo, and M. Andreoni. 2002. Discordance between genotypic and phenotypic drug resistance profiles in human immunodeficiency virus type 1 strains isolated from peripheral blood mononuclear cells. J. Clin. Microbiol. 40:335-340.
13. Shafer, R. W. 2002. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin. Microbiol. Rev. 15:247-277.
14. Yeni, P. G., S. M. Hammer, M. S. Hirsch, M. S. Saag, M. Schechter, C. C. Carpenter, M. A. Fischl, J. M. Gatell, B. G. Gazzard, D. M. Jacobsen, D. A. Katzenstein, J. S. Montaner, D. D. Richman, R. T. Schooley, M. A. Thompson, S. Vella, and P. A. Volberding. 2004. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 292:251-265.
15. Young, S. D., S. F. Britcher, L. O. Tran, L. S. Payne, W. C. Lumma, T. A. Lyle, J. R. Huff, P. S. Anderson, D. B. Olsen, S. S. Carroll, et al. 1995. L-743,726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 39:2602-2605.